MedPath

Intraoperative Cell Salvage and Hemodilution Technique in Scoliosis Surgery

Not Applicable
Completed
Conditions
Adolescent Idiopathic Scoliosis
Interventions
Procedure: cell salvage technique
Procedure: acute normovolemic hemodilution
Registration Number
NCT02112409
Lead Sponsor
University of Malaya
Brief Summary

Surgical correction of scoliosis with instrumentation carries significant blood loss and needs for blood transfusion with its inherent risk and cost. In recent years, there is an increased interest in utilizing autologous blood as part of perioperative blood conservation strategy.

The foremost mechanical methods of perioperative conservation of red blood cells including intraoperative cell salvage (ICS) and acute normovolemic hemodilution (ANH). They should be considered in all cases where significant blood loss (\>1000 ml) or \>20% estimated blood volume is expected, in patients with multiple antibodies or rare blood types and those who refuse allogenic blood products.

Literature search has revealed that both cell salvage method and ANH utilized in elective surgeries are capable of minimizing allogenic blood transfusion respectively. Surgeries which are of significant relevance are aortic surgery, cardiac surgery and arthroplasty orthopaedic surgery. Combining the above two techniques such as in ATIS trial 2002 also shows that it is safe and significantly reduced allogenic blood requirements in aortic surgery. However till date, there is still lack of strong evidence that autologous blood transfusion technique is beneficial for scoliosis surgery in reducing allogenic blood transfusion.

Hypothesis:

The investigators hypothesize that the addition of ANH to ICS would confer additional benefit than using cell saver alone. By combining cell saver with hemodilution technique, the difference between pre-operative and post-operative Hemoglobin level will be smaller than using cell saver technique alone, hence minimizing the variation in perioperative Hemoglobin level - a predictor of allogenic blood transfusion.

Detailed Description

Patients who meet the inclusion criteria are enrolled in the study. They are assigned to 2 arms of study group using concealed allocation method. A computerized random-number generator will be used to formulate an allocation schedule. Group A will receive cell salvage and acute normovolemic hemodilution during operation; Group B will only receive cell salvage as sole autologous transfusion strategy.

Members of the research team should attend all operations and record all data. Anaesthetic technique including drugs usage, equipments and monitoring devices are standardized as per protocol. Intraoperative fluid management is recorded in details.

All patients enrolled in the study (group A and B) underwent cell saver technique during surgery using Cell Saver® 5+ autologous blood recovery system-Haemonetics devices. All patients allocated in group A also received additional acute normovolemic hemodilution (ANH) after induction of anaesthesia. As a standardization measure, before starting skin incision, 500ml blood will be collected from the radial artery to a standard blood collection bag and stored as CPD blood at ambient temperature. Simultaneously, 500ml Voluven® (6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride) will be infused through a peripheral vein.

All autologous blood will be re-infused back to patient at surgery completion or within 6 hours of withdrawal. Autologous blood will be given to patient during surgery at any point if there are 30% or more body blood volume loss.

Allogenic blood will be administered when the intraoperative hemoglobin concentration fell below 8g/dl despite completion of autologous blood transfusion or when autologous blood not available; adequate volume correction by mean of collected autologous blood and crystalloid fluid administration, or when presence of ischemic electrocardiogram changes (2mV ST segment elevation or depression on 3 leads monitoring); persistent hypotension or tachycardia \>20% from baseline.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
44
Inclusion Criteria
  • Elective single stage posterior spinal fusion for scoliosis corrective surgery
  • Diagnosis of idiopathic scoliosis
  • Age >10 and <25
  • ASA I or II
  • Preoperative Hemoglobin > 10 g/dL
  • Preoperative Platelet > 150,000/L
  • Clinically fit for surgery
  • Written informed consent
Exclusion Criteria
  • Patient's refusal of homologous blood
  • Hematological disorder rendering either transfusion technique inappropriate
  • Patients who received anticoagulants and antiplatelets perioperatively
  • Severe cardiac disease (Aortic stenosis or cardiac ejection fraction <40%; Myocardial infarction in the previous 6 Months; Myocardial ischaemia on resting Electrocardiogram)
  • Severe pulmonary disease (FEV1 50% predicted, PaO2 9 kpa on air)
  • Preoperative creatinine >200 mmol/L
  • AST >100 IU/L

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
cell salvage and hemodilution techniquecell salvage techniquecell salvage technique throughout scoliosis corrective surgery; Acute normovolemic hemodilution technique commenced after induction of anaesthesia and prior the starting of surgery.
cell salvage and hemodilution techniqueacute normovolemic hemodilutioncell salvage technique throughout scoliosis corrective surgery; Acute normovolemic hemodilution technique commenced after induction of anaesthesia and prior the starting of surgery.
cell salvagecell salvage techniquecell salvage technique throughout scoliosis corrective surgery
Primary Outcome Measures
NameTimeMethod
Difference in pre-operative and post-operative hemoglobin levelat 0 hour and 24 hour post-operation

Laboratory testing for hemoglobin level will be carry out at 0 hour and 24 hour post-operation.

Secondary Outcome Measures
NameTimeMethod
Perioperative requirement of allogenic blood transfusionone week post-operation

participants (patients) will be followed for the duration of hospital stay, an expected average of one week.

Trial Locations

Locations (1)

University Malaya Medical Centre

🇲🇾

Kuala Lumpur, Malaysia

© Copyright 2025. All Rights Reserved by MedPath